BioCryst Pharmaceuticals | BCRX - 销售成本

金融业

USD

USD 557.85M

现金及等价物

USD 154.97M

USD 3.84M

USD 484.68M

USD 208.85M

USD 828.6M

股息收益率

0

USD 98.47M

USD 51.7M

536

EPS每股收益

USD 0.3

股本和储备

USD -454.29M

USD 214.41M

债务利息支出

USD 21.71M

USD -0.13

USD 395.4M

USD 1.97B

USD 78.4M

USD 119.79M

USD 98.47M

普通股股本

USD 255.27M

6.84

USD 248.02M

USD 218.25M

销售和管理费用

USD 63.98M

USD 6.06M

贸易债权人

USD 11.46M

应收帐款人

USD 110.76M

	销售成本	更改		日
Alnylam Pharmaceuticals	USD 298.45M		87.33M	2026-06
BioCryst Pharmaceuticals	USD 3.84M		5.68M	2026-06
Chugai Pharma	JPY 104.22B		11.43B	2026-06
Daiichi Sankyo	JPY 124.29B		6.02B	2026-06
Gilead Sciences	USD 1000M		445M	2026-06
GlaxoSmithKline	GBP 2.07B		192M	2026-06
Glaxosmithkline	GBP 1.88B		1.6B	2026-03
Incyte	USD 104.96M		457K	2026-06
Ionis Pharmaceuticals	USD 2.74M		261K	2026-06
Karyopharm Therapeutics	USD 1.34M		139K	2026-03
Neurocrine Biosciences	USD 39.4M		25.6M	2026-06
Novavax	USD 22.1M		608K	2025-12
PTC Therapeutics	USD 39.61M		23.31M	2026-03
Regeneron Pharmaceuticals	USD 576.5M		92.9M	2026-06
Roche Holding	CHF 7.85B		630M	2026-06
Sarepta Therapeutics	USD 150.1M		40.64M	2026-06
Ultragenyx Pharmaceutical	USD 30M		1000K	2026-03
Vertex Pharmaceuticals	USD 489.2M		96.4M	2026-06